

## INFORMAȚII PERSONALE

**ANCUTA CODRINA IRENA MIHAELA**

 Iasi, Romania

 0740036387

 codrina\_ancuta@yahoo.com

Data nașterii 05 Feb1970 | Naționalitatea Romana

## EXPERIENȚA PROFESIONALĂ UNIVERSITARA

|                    |                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Feb 2015</b>    | <b>Conferentiar universitar dr.</b><br><b>Medic primar Reumatologie</b><br><b>Medic primar Recuperare, Medicină Fizică și Balneologie</b><br>Disciplina Reumatologie-Recuperare, Medicina Fizica si Balneologie<br>Facultatea de Medicină<br>Universitatea de Medicină și Farmacie „Grigore T. Popa“ Iași<br><b>Tipul/sectorul de activitate:</b> Institutie de Invatamint Superior |
| <b>2004 - 2015</b> | <b>Sef lucrari dr.</b><br><b>Medic primar Reumatologie</b><br><b>Medic primar Recuperare, Medicină Fizică și Balneologie</b><br>Disciplina Reumatologie-Recuperare, Medicina Fizica si Balneologie<br>Facultatea de Medicină<br>Universitatea de Medicină și Farmacie „Grigore T. Popa“ Iași<br><b>Tipul/sectorul de activitate:</b> Institutie de Invatamint Superior              |
| <b>1999 - 2004</b> | <b>Asistent universitar dr.</b><br>Disciplina Reumatologie-Recuperare, Medicina Fizica si Balneologie<br>Facultatea de Medicină<br>Universitatea de Medicină și Farmacie „Grigore T. Popa“ Iași<br><b>Tipul/sectorul de activitate:</b> Institutie de Invatamint Superior                                                                                                           |
| <b>1995 - 1999</b> | <b>Preparator universitar</b><br>Disciplina Balneofizioterapie - Reumatologie<br>Facultatea de Medicină<br>Universitatea de Medicină și Farmacie „Grigore T. Popa“ Iași<br><b>Tipul/sectorul de activitate:</b> Institutie de Invatamint Superior                                                                                                                                   |

## EXPERIENȚA PROFESIONALĂ MEDICALA

|                 |                                                                                                                                                                                                                                                                                          |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Ian 2016</b> | <b>Coordonator EULAR IMAGING CENTER</b><br>Universitatea de Medicina si Farmacie "Grigore T. Popa" Iași<br>Afiliata <i>EULAR Network of Imaging Training Centers</i> 2016-2021<br><b>Tipul/sectorul de activitate:</b> Training capilaroscopie in SSC si boli din spectrul sclerodermiei |
| <b>Ian 2013</b> | <b>Șef Sectie Clinica</b><br>Reumatologie 2<br>Spitalul Clinic de Recuperare Iași, str. Pantelimon Halipa nr.14<br><b>Tipul/sectorul de activitate:</b> Asistenta medicala,                                                                                                              |

|                  |                                                                                                                                                                                                                                                                                      |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Ian 2013</b>  | <b>Coordonator Centru EUSTAR 162</b><br>Clinica Reumatologie 2<br>Spitalul Clinic de Recuperare Iași, str. Pantelimon Halipa nr.14<br><b>Tipul / sectorul de activitate:</b> Studiul și cercetarea sclerodermiei sistemice                                                           |
| <b>2008-2013</b> | <b>Medic primar Reumatologie</b><br><b>Medic primar Recuperare Medicală, Medicina Fizică și Balneologie</b><br>Clinica Reumatologie<br>Spitalul Clinic de Recuperare Iași, str. Pantelimon Halipa nr.14<br><b>Tipul / sectorul de activitate:</b> Spital Clinic Universitar          |
| <b>2003-2008</b> | <b>Medic primar Reumatologie</b><br><b>Medic specialist Recuperare Medicală, Medicina Fizică și Balneologie</b><br>Clinica Reumatologie<br>Spitalul Clinic de Recuperare Iași, str. Pantelimon Halipa nr.14<br><b>Tipul / sectorul de activitate:</b> Spital Clinic Universitar      |
| <b>1999-2003</b> | <b>Medic specialist Reumatologie</b><br><b>Medic rezident Recuperare Medicală, Medicina Fizică și Balneologie</b><br>Clinica de Reumatologie<br>Spitalul Clinic de Recuperare Iași, str. Pantelimon Halipa nr.14<br><b>Tipul / sectorul de activitate:</b> Spital Clinic Universitar |
| <b>1996-1999</b> | <b>Medic rezident Reumatologie</b><br>Clinica de Reumatologie<br>Spitalul Clinic de Recuperare Iași, str. Pantelimon Halipa nr.14<br><b>Tipul / sectorul de activitate:</b> Spital Clinic Universitar                                                                                |

## EDUCAȚIE ȘI FORMARE

|             |                                                                                                                                                                                                                                                                                                                                                                       |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>2008</b> | <b>Medic primar Recuperare Medicală, Medicina Fizică și Balneologie</b><br>OMS 1971/03.12.2008 (media promovare 10.00)<br>Universitatea de Medicină și Farmacie „Grigore T. Popa” Iași                                                                                                                                                                                |
| <b>2005</b> | <b>Doctor în Medicină</b> (seria E nr. 0002743, ordin MEC 3824 din 03.05.2006)<br>Teza: <i>Miopatia inflamatorie în poliartrita reumatoidă/ Inflammatory myopathy in rheumatoid arthritis</i><br>coordonator doctorat: prof univ dr George Ioan Pandelescu;<br>1998-2005: studii doctorale; susținere publică teza doctorat iulie 2005                                |
| <b>2003</b> | <b>Supraspecializare în Boli osoase endocrino-metabolice</b> (certificat absolvire curs seria D Nr.0011216; certificat supraspecializare Patologie osoasă endocrino-metabolică seria C Nr.013718)<br>Centrul Național de Perfecționare Postuniversitară a Medicilor, Farmaciștilor, altui personal cu Studii Superioare și Asistenților Medicali Ministerul Sănătății |
| <b>2003</b> | <b>Medic primar Reumatologie</b><br>OMS nr. 846/ 12.09.2003 (medie promovare 9.66)<br>Universitatea de Medicină și Farmacie „Grigore T. Popa” Iași                                                                                                                                                                                                                    |
| <b>2002</b> | <b>Medic specialist Recuperare Medicală, Medicina Fizică și Balneologie</b><br>OMS nr 256/11.04.2002 (media promovare 9.33)<br>Universitatea de Medicină și Farmacie "Grigore T. Popa" Iași                                                                                                                                                                           |

|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | Studii postuniversitare rezidențiat reumatologie                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>1999</b>                       | <b>Medic specialist Reumatologie</b><br>OMS nr. 900/ 20.10.1999 (medie promovare 9.17)<br><b>Medic rezident Recuperare Medicală, Medicina Fizică și Balneologie</b><br>Universitatea de Medicină și Farmacie "Grigore T. Popa" Iași<br>Studii postuniversitare rezidențiat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>1996</b>                       | <b>Medic rezident Reumatologie</b><br>OMS nr. 715/27.03.1996<br>Universitatea de Medicină și Farmacie "Grigore T. Popa" Iași<br>Studii postuniversitare rezidențiat reumatologie                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>1988- 1994</b>                 | <b>Diploma de medic - doctor:</b> diploma M nr. 041128 (media generala 9.98; media generala licenta 9.99) (sesiunea sept 1994)<br>Universitatea de Medicina si Farmacie "Grigore T. Popa" Iași                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>1984-1988</b>                  | <b>Liceul “Emil Racovița”,</b> profil matematica-fizica; absolventa a promotiei iunie 1998, diploma de bacalaureat seria E Nr.39358 (media generala examen bacalaureat 9.62)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Alte cursuri și competențe</b> | <ul style="list-style-type: none"> <li>Coordonator Acreditat program de pregătire rezidenți: specialitatea Reumatologie; specialitatea Recuperare, Medicină Fizică și Baneologie</li> <li><i>Certified Clinical Densitometrist (CCD) - The International Society for Clinical Densitometry</i> - ISCD September 30, 2006 to September 30, 2011</li> <li>Manifestări acreditate de CMR evaluate cu credite în cadrul programului de educație medicală continua</li> </ul> <b>Cursuri postuniversitare Internationale</b> <ul style="list-style-type: none"> <li>2015, <i>Digital Ulcer Systemic Scleroderma Masterclass</i>, 19 Dec, Bucharest, Romania</li> <li>2015, <i>Digital Ulcer Systemic Scleroderma Masterclass</i>, 11-12 July, Bucharest, Romania</li> <li>2015, <i>4<sup>th</sup> Annual Meeting of the Lupus Academy</i>, 28 Feb-01March, Rome, Italy (bursary)</li> <li>2014, <i>Imagistica in bolile reumatice</i>, 01 oct, Bucuresti, Romania</li> <li>2014, <i>3<sup>rd</sup> Annual Meeting of the Lupus Academy</i>, 7-9 March, Berlin, Germany (bursary)</li> <li>2013, <i>Pain Refresher Course</i>, 2<sup>nd</sup> May, Singapore</li> <li>2013, <i>2<sup>nd</sup> SE Europe Course Systemic Lupus Erythematosus</i>, 25 Sep, Bucharest, Romania</li> <li>2012, <i>APLAR Musculoskeletal Ultrasound Course in Rheumatology</i>, 10-14 Sep, Dead Sea, Amman, Jordan</li> <li>2012, <i>Al doilea Curs International de Ecografie Musculoscheletala</i> (patronaj stiintific EULAR), 8-10 martie, Bucuresti, Romania</li> <li>2011, <i>Workshop: Methodentransfer und neue knoepte rheumatologie</i>, 2-4 Jun, Chisinau, Moldova.</li> <li>2011, <i>ISCD Clinician Bone Densitometry Course</i>, 25-26 feb 2011, Bucharest, Romania.</li> <li>2010, <i>ISCD and IOF FRAX Initiative: Interpretation and Use of FRAX in Clinical Practice</i>, 11-13 Nov, Bucharest, Romania.</li> <li>2009, <i>Osteoporoză cu Certificare în Osteodensitometrie, IOF-OsArt</i>, 27-28</li> </ul> |

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>May, Sinaia, Romania.</p> <ul style="list-style-type: none"> <li>• 2009, 6<sup>th</sup> RCRD International Workshop: <i>Up-to-date in Rheumatology</i>, 27-29 Apr, Bucharest, Romania</li> <li>• 2008, <i>The 1<sup>st</sup> Quantitative Ultrasound Densitometry Course</i>, 3-4 July, Bucharest &amp; Iasi, Romania</li> <li>• 2008, <i>Scleroderma Skin Scoring EUSTAR Course</i>, 11 July, Cluj-Napoca, Romania</li> <li>• 2008, <i>Academy of Rheumatology</i>, 18-20 Dec, Cairo, Egipt</li> <li>• 2008, <i>Program educational de armonizare a managementului PR precoce in concordanta cu recomandarile EULAR- Eupera</i>, Sanofi Aventis (Universitatea Paris VII Franta) <a href="http://www.eupera.org">www.eupera.org</a></li> <li>• 2007, Workshop <i>New evidence-based pain control: oxycodone in severe somatic, neuropatic and visceral pain</i>, 23-27 March, Paris, France</li> <li>• 2007, 4<sup>th</sup> RCRD (Research Centre on the pathology and treatment of Rheumatic Disorder) International Workshop: <i>Outcomes in Rheumatology</i>, 6-8 Dec, Bucharest, Romania (European Commission FP6)</li> <li>• 2007, <i>Musculoskeletal ultrasound course</i>, 19-21 Jan, Bucharest, Romania</li> <li>• 2007, <i>Osteoporoza cu Certificare in Osteodensitometrie</i>, 11-14 apr, Cluj-Napoca, Romania</li> <li>• 2007, <i>14<sup>th</sup> EULAR Intermediate Sonography Course</i>, 10-13 June, Sitges, Barcelona, Spania (bursa EULAR)</li> <li>• 2006, 1<sup>st</sup> RCRD International Workshop: <i>Advanced Techniques in Bone Research</i>, 28-30 Sep Bucuresti, Romania</li> <li>• 2006, <i>ISCD Bone densitometry Course</i>, 29-30 Sep, Bucuresti, Romania</li> <li>• 2006, <i>Advancing arthritis therapy: addressing patient needs</i>, 4 Feb, Seville Spain</li> <li>• 2005, <i>International Musculo-skeletal Sonography Course</i> (EULAR, OSART), 13-16 Apr, Cluj-Napoca, Romania</li> <li>• 2004, <i>9<sup>th</sup> EULAR Sonography Course (from introductory to advanced practical course on musculoskeletal sonography)</i>, 9-12 Dec, Paris, France (bursa EULAR)</li> <li>• 2004, <i>1<sup>st</sup> European Course – Capillaroscopy and Rheumatic Diseases</i>, 10-12 Sep, Genova, Italy (bursa EULAR)</li> <li>• 2000, <i>John Humphrey International Course of Immunology on self-tolerance and self-recognition</i>, 15-19 May, Sinaia, Romania (patronaj European Federation of Immunological Societies, RSI, Romanian Society for Immunology – Iasi Branch)</li> <li>• 2000, <i>6<sup>th</sup> EULAR Postgraduate Course in Rheumatology</i>, 18-27 June 2000, Nice, Franta (sub patronaj EULAR) (bursa EULAR);</li> <li>• 1992, 30 aug-03 sep 1992, <i>John Humphrey Course on Tumor Immunology</i>, Iasi, Romania</li> </ul> <p><b>Cursuri Good Clinical Practice (GCP)</b></p> <ul style="list-style-type: none"> <li>• 2012, CME Program SCEPTEr, Introduction to the Clinical Drug Development Process: ICH Good Clinical Practice for Clinical Trial Sites, web-training,</li> <li>• 2012, Quintiles Global Learning &amp; Development, Introduction to the Clinical Drug Development Process: ICH Good Clinical Practice for Clinical Trial Sites, web-training</li> <li>• 2011, Pfizer GCP for Investigational Site Staff, Pfizer Partner Learning Solution, web-training</li> <li>• 2011, FLEX-LA294 Investigator Meeting, 28-29 apr, Barcelona, Spain</li> </ul> <p><b>Nationale</b></p> <ul style="list-style-type: none"> <li>• <b>Management Spitalicesc</b>, Scoala Nationala de Sanatate Publica si Management</li> </ul> |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>Sanitar, 14.02-28.03.2008, Bucuresti, Romania (seria A, nr. 00331);</p> <ul style="list-style-type: none"> <li>• Curs <b>Laser-terapie</b>, 01.03-31.05.2001, Iasi, Romania, certificate de absolvire curs seria A, nr 0009588</li> <li>• Curs intensiv <b>Metode moderne de tratament al copilului spastic</b>, 21-23.09.2000, Bucureti, Romania</li> <li>• Curs postuniversitar <b>Algeziologie</b> (durerea si tratamentul ei), 23.04-21.05.1999, UMF "Gr.T.Popa" Iasi (certificat de absolvire seria B, nr 0003658)</li> </ul> |
|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## COMPETENTE PERSONALE

| Limbi străine cunoscute | INTELEGERE                                                                                                                                                                                                                                                                                                            |        | VORBIRE                    |              | SCRIERE |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------|--------------|---------|
|                         | Ascultare                                                                                                                                                                                                                                                                                                             | Citire | Participare la conversație | Discurs oral |         |
| Engleza                 | B2                                                                                                                                                                                                                                                                                                                    | B2     | B2                         | B2           | B2      |
|                         | <ul style="list-style-type: none"> <li>• atestat EuroEd, certificat absolvire nr 019/05 dec 2010</li> <li>• certificat de absolvire Funny English center Curs avizat de Ministerul Invatamintului nr 25410/18.03.1997 si Autorizat Consiliul National de Formare a Adultilor decizia 22/240 din 11.04.2008</li> </ul> |        |                            |              |         |
| Franceza                | B2                                                                                                                                                                                                                                                                                                                    | B2     | B2                         | B2           | B2      |
|                         | <ul style="list-style-type: none"> <li>• atestat DALF- Diplome Approfondi de la Langie Francais 12/04/1995 – no 04000100097</li> </ul>                                                                                                                                                                                |        |                            |              |         |

|                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Competențe de comunicare</b>                | <ul style="list-style-type: none"> <li>• Abilități de comunicare dobândite în activitatea didactica si medicala / Capacitate de lucru în echipă/ Abilități interpersonale</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Competențe organizaționale/ manageriale</b> | <ul style="list-style-type: none"> <li>• Leadership (Sef Clinica Reumatologie 2, coordonator rezidentiat, coordonator centru EUSTAR, coordonator EULAR Imaging Center)</li> <li>• Membru fondator &amp; Presedinte RHEUMA NE, membru fondator Asociatia Recuperare Nord-Est</li> <li>• Membru în Comitete de organizare Congrese Naționale și Internaționale, alte manifestări științifice</li> <li>• Competențe organizaționale și manageriale dobândite în coordonarea echipelor de lucru în cadrul spitalului, disciplinei, colectivelor de cercetare</li> <li>• Cursuri Postuniversitare: Coordonator (8 cursuri)- Lector (110 cursuri)</li> <li>• Lector/Coordonator Masterat (2)</li> <li>• Îndrumare lucrări de licență (74 lucrări)</li> <li>• Participare la studii internaționale</li> </ul> |
| <b>Competențe dobândite la locul de muncă</b>  | <ul style="list-style-type: none"> <li>• Director/ Membru echipe proiecte cercetare/ <i>study coordinator</i></li> <li>• Cursuri postuniversitare absolvite 36</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Competențe informatice</b>                  | <ul style="list-style-type: none"> <li>▪ Deprinderi cercetare asistată de calculator, elaborare și analiza baze de date</li> <li>▪ Buna cunoastere a sisteme de operare Windows, Microsoft Excel, Microsoft Word, Microsoft Power Point</li> <li>▪ Operare și aplicații program SPSS</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Alte competente</b>                         | <ul style="list-style-type: none"> <li>▪ Membru în Comisii admitere/licență/masterat</li> <li>▪ Membru în Comisii examen medic specialist/primar</li> <li>▪ Membru în Comisii pentru ocuparea forței de muncă în învățământul medical superior preparator/asistent universitar</li> <li>▪ Raportor Științific Comisii Doctorat</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Permis de conducere</b>                     | Categoria B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## INFORMATII SUPLIMENTARE

|                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Publicații</b></p> <p><b>Conferințe/ Prezentări<br/>manifestări științifice</b></p> <p><b>Proiecte/<br/>Granturi/<br/>Contracte de cercetare</b></p> | <ul style="list-style-type: none"> <li>• <b>articole publicate in extenso in reviste cotate ISI: (47)</b> (18 in calitate de autor principal) (vezi lista completa lucrari anexata);</li> <li>• <b>articole publicate in rezumat in reviste cotate ISI: (86)</b> (42 autor principal, 44 coautor) (vezi lista completa lucrari anexata);</li> <li>• <b>articole in extenso in reviste indexate in BDI: (85)</b> (39 autor principal, 46 coautor) (vezi lista completa lucrari anexata);</li> <li>• <b>articole in rezumat in reviste indexate in BDI sau volume manifestari stiintifice cu si fara ISBN: (76)</b> (39 autor principal, 37 coautor);</li> <li>• <b>carti, manuale, monografii: carte internationala</b> (8 capitole); <b>carte nationala</b> (1 editor, 4 autor unic, 1 membru in colectiv de autori, 13 autor capitol);</li> </ul> <p><b>201 prezentari - 75 comunicari orale, 126 postere</b> (vezi lista completa lucrari anexata)</p> <ul style="list-style-type: none"> <li>• international - 24 (4 autor principal) comunicari orale</li> <li>• national - 51 (25 autor principal) comunicari orale</li> <li>• international 81 (44 autor principal) postere</li> <li>• national 45 (23 prim autor) - postere</li> </ul> <ul style="list-style-type: none"> <li>• <b>granturi internationale (14)</b></li> </ul> <p><b>2 director de grant international</b></p> <ul style="list-style-type: none"> <li>• <b>IASP Grant: Musculoskeletal pain academy</b>, 2011, IASP Developing Countries Project: Initiative for improving pain education; jul2011-jul2012; (acord UMF "Gr.T.Popa" Iasi nr.12119/28.06.2011);</li> <li>• <b>EUSTAR Clinical Project CP34: Early Accelerated Atherosclerosis in Systemic Sclerosis (SSAS)</b>, grant EUSTAR 2011-2015;</li> </ul> <p><b>2 director partener national in consortiu international</b></p> <ul style="list-style-type: none"> <li>• <b>EULAR Orphan Disease Program</b> <i>Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis</i>; Chief Investigator Professor Ariane Herrick (University of Manchester); Funder EULAR Orphan Disease Program (Funding Reference Number R111788); Acord colaborare nr. 13517/14.07.2011 Universitatea Manchester-U.M.F. "Gr.T.Popa" Iasi (jul2011-ian2014)</li> <li>• <b>International EU-funded Research Project (FP7): DEsschipher, to decipher the optimal management of systemic sclerosis</b></li> </ul> <p><b>10 membru in colective internationale</b></p> <ul style="list-style-type: none"> <li>• <b>IASP Grant IASP Developing Countries Project: Initiative For Improving Pain Education - Grant IASP (International Association for the Study of Pain)</b>; Manager de proiect dr. Jaba Irina 05.2009-05.2010;</li> <li>• <b>PROTOCOL QUEST-RA 2009-2011: Quantitative Patient Questionnaire Monitoring in Standard Clinical Care of Patients with Rheumatoid Arthritis (QUEST-RA)</b>, Manager de proiect Tuulikki SOKKA (Finland), 2009-2011</li> <li>• <b>PROTOCOL QUEST-RA 2013-2014: Treating Rheumatoid Arthritis to Target: Are Recommendations met? A Multinational Study of Patients with Rheumatoid Arthritis who Receive Usual Care in 33 Countries</b>; Manager de proiect Tuulikki SOKKA (Finland), 2013-2014</li> <li>• <b>EUSTAR Project CP18: Digital Ulcers secondary to Systemic sclerosis AC-052-513</b> - grant EUSTAR Research group and Actelion EUSTAR (Project leader: Prof. Ulrich Walker; Actelion Project leader: Monika Brand; Project manager: Dr Rebecca Hollaender) (Nov 2009 – Oct 2010)</li> </ul> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



### Participare la studii clinice internationale

- **EUSTAR Clinical Project: Very Early Diagnosis of Systemic Sclerosis VEDOSS**, 2010-2015 (2020), , PROJECT manager: prof dr. Marco Matucci Cerinic ;
- **EUSTAR Clinical Project: MEDS**
- **EUSTAR Clinical Project IMPRESS 2**: International Multi-centric Prospective study on pregnancy in systemic sclerosis, Directori proiect: Monika Ostensen University of Trondheim Norway, Angela Tincani University of Brescia Italy, Antonio Brucato, Ospedale Reuniti Bergamo Italy. oct 2013
- **EUSTAR Clinical Project CP11: Prevalence and clinical associations of capillaroscopic scleroderma patterns in the EULAR Scleroderma Trial And Research group (EUSTAR) database of patients with systemic sclerosis**. Project Francesca Ingegnoli, (EUSTAR UCN 110), 2011
- **EUSTAR Clinical Project CP14: Biologics in systemic sclerosis patients treated with Rituximab. If you have SSc patients treated with Rituximab**; PI O Distler, UCN 006, Zurich;
- **PROTOCOL IRIS: International Recommendation Implementation Study – a multinational observational study to investigate the impact of recent treatment recommendations for the treatment of patients with rheumatoid arthritis using web-based patient monitoring (METEOR)**; primary investigator Robert B.M. Landewé (22.05.2013)

### granturi nationale (4) (membru in echipa grant)

- **GRANT CNC SIS: Platforma de cercetari fizio-farmacologice si clinice asupra mecanismelor durerii oncologice si non-oncologice**; cod CNC SIS 68; Contract 11/15.09.2006; 2006-2008; director proiect OC MUNGIU (membru in echipa de cercetare) (finantare CNC SIS) in cadrul **Centrului pentru Studiul si Terapia Durerii de la Universitatea de Medicina si Farmacie "Grigore T. Popa" Iasi**;
- **PROIECT POSCCE-A2-O2.2.1-2007-1+Capacitati-I-2007-2, IMPACT IV sesiunea Sept 2007: Centru de cercetare a lupusului eritematos sistemic si bolilor autoimune inrudite (CCLESAI)**, 2007-2008, proiect finantat (ID 1071); director proiect prof Chiriac R; (director stiintific in echipa proiectului)
- **POSCCE A2-O2.2.1-2009-4 Operatiunea 2.2.1 Centru de cercetare a lupusului eritematos sistemic si bolilor autoimune inrudite**, Director stiintific,
- **PROIECT POSDRU 81/3.2/S/55648, Formare profesionala pentru implementarea noilor tehnologii in sistemul de sanatate PERFORMED**, director proiect – prof dr HD Bolosiu, UMF I Hatieganu Cluj-Napoca, 2010-2013, competitie, fonduri 5.000.000 EURO (realizarea si prezentarea cursuri, Sesiunea de formare NE,

- **studii multicentrice postmarketing (14)** (4 investigator principal in studii internationale; 10 investigator principal in studii nationale)
- **studii multicentrice randomizate (53)** (9 investigator principal; 44 – subinvestigator/coordonator de studiu)
- **PROTOCOL ML25228 REPEAT: Studiu observational post-marketing cu Mabthera prescris pacientilor TNF-IR, pentru evaluarea eficacitatii si sigurantei curelor repetate in practica medicala clinica de rutina (Repeated Courses in routine Clinical Practice)** (2012-2013) sponsor Roche
- **PROTOCOL ML25332 STONE: Studiu observational post-marketing cu Ro-actemra (tocilizumab) prescris pacientilor DMARD-IR pentru evaluarea eficacitatii si sigurantei administrarii in practica clinica de rutina**; sponsor Roche (2009-2011)
- **PROTOCOL ML27953 FAST2 SWITCH: Studiu non-interventional prospective multicentric pentru a evalua eficacitatea si siguranta rituximab la pacienti cu artrita**

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>reumatoida active care au avut un raspuns inadecvat sau intolerant la un agent anti-TNF (2011) sponsor Roche</p> <ul style="list-style-type: none"> <li>• <b>PROTOCOL ELOCVENT:</b> Evaluarea impactului osteoporozei postmenopauza asupra calitatii vietii pacientelor – studiu observational sponsor Servier; 04.2008-07.2008</li> <li>• <b>PROTOCOL BEL115014 SESAME:</b> Systemic Lupus Erythematosus in CEE Settings: Romania, Poland, Hungary. An insight on Medical, Economic and Social Burden (2011-2012); sponsor: GSK.</li> <li>• <b>PROTOCOL P10-599:</b> An observational study of the impact of the anti-cyclic citrullinated peptide antibody (anti-CCP) status on the management of patients with early rheumatoid arthritis (study HU-08-02): a multi-country, multi-center, post-marketing observational study in the routine clinical use (2010-2011); sponsor: Abbott.</li> <li>• <b>PROTOCOL P10-919 EviraEAST:</b> Evaluation of clinical outcome, treatment compliance and tolerability of Humira (adalimumab) in patients with active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Eastern European countries: a multi-country, multicenter post-marketing observational study in routine clinical use (2009-2011) (PMOS-CE-08-01); sponsor: Abbott.</li> <li>• <b>PROTOCOL PMOS P10-733 DEXA:</b> Evaluation of the Role of Adalimumab on extra-articular manifestation- bone metabolism and bone mineral density in patients with active Rheumatoid Arthritis (2011-2012) (centre 42146); sponsor: Abbott.</li> <li>• <b>PROTOCOL P12-768:</b> Multi-country post-marketing observational study on maintenance of effectiveness of adalimumab (Humira) in patients with ankylosing spondylitis and psoriatic arthritis – a multi-country observational study in routine use in Central and Eastern Europe (nov 2011-2012 ); sponsor Abbott;</li> <li>• <b>PROTOCOL P13-682 IDEA:</b> Impactul adalimumab (Humira) ca terapie asupra utilizării anumitor resurse legate de îngrijirea sănătății și asupra concediului medical la pacienții cu spondilită anchilozantă, în practica clinică curentă (2012-2014), sponsor Abbott;</li> <li>• <b>PROTOCOL P13-683 PACE:</b> Evaluarea activității fizice la pacienții cu poliartrita reumatoida tratați cu adalimumab în practica clinică de rutină (PACE)- studiu observational postmarketing, multinational, multicentric privind practica curentă în Europa Centrală și de Est (2012-2014); sponsor Abbott;</li> <li>• <b>PROTOCOL IMM11-0138 ALIGN:</b> Epidemiological/HEOR Study– Multi-country, cross section <u>AL</u> study to determine patient specIfic and <u>General</u> beliefs towards medicatio<u>N</u> and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (IMID) (2012-2013); sponsor Abbott;</li> <li>• <b>PROTOCOL 10297 PROOF:</b> Pacienți cu spondiloartrită axială: registru multi-național al caracteristicilor clinice, inclusiv progresia radiologică, și al poverii bolii pe parcursul a 5 ani în condiții reale (2014-2019); sonsor Abbvie;</li> <li>• <b>PROTOCOL IMM-12-0118:</b> Evaluation of management of patients with early rheumatoid arthritis (RA) in routine clinical practice based on Treat to Target (T2T) principles, (2014-2015), sponsor Abbvie</li> <li>• <b>PROTOCOL IM 128-027:</b> Studiu de faza 2 multicentric randomizat dublu orb controlat placebo de evaluate a siguranței și eficacității BMS-913699 vs placebo administrat pe fondul standardelor de îngrijire restricționat, ca tratament al subiecților cu lupus eritematos sistemic activ; sponsor BMS Corporation Belgia; <b>Investigator Principal (2014)</b></li> <li>• <b>PROTOCOL A3921187 (9002-0249):</b> A Phase 3b/4 randomized double blind study of 5 mg of Tofacitinib with and without Methotrexate in comparison to Adalimumab with Methotrexate in subjects with moderately to severe active rheumatoid arthritis. <b>Investigator principal (2014)</b></li> <li>• <b>PROTOCOL G0-VIBRANT. COD CNT0148PSA3001</b> A multi-centric, randomized, double blind placebo controlled trial of golimumab, an anti TNF monoclonal antibody, administered intravenously, in subjects with active psoriatic arthritis. Phase3. <b>Investigator principal (2014)</b></li> <li>• <b>PROTOCOL G0-ALIVE. COD CNT0148AKS3001</b> A multi-centric, randomized, double blind placebo controlled trial of golimumab, an anti TNF monoclonal antibody, administered intravenously, in subjects with active ankylosis spondylitis. Phase3. <b>Investigator principal (2014)</b></li> </ul> |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



- **PROTOCOL GLASS:** A multi-center, randomized double-blind parallel group study on the therapeutic efficacy and safety of febuxostat (taken once daily) and the therapeutic efficacy and safety of allopurinol on serum urate concentration in subjects suffering from hyperuricemia and gout (MEIN/11/FEN-Gou/001; CRO InnoPharma SRL, Sponsor MIOL, 2014-2015)
- **PROTOCOL A9391010:** a phase 2, randomized, double blind assessment of efficacy and safety of pf-04171327 (1, 5, 10, 15 mg dose, daily) compared to 5 mg and 10 mg prednisone daily and placebo daily in subjects with rheumatoid arthritis over an 8 week period followed by a 4 week period of tapering of study drug; CRO; Parexel; sponsor: Pfizer; **Investigator principal (2014)**
- **PROTOCOL B1801315:** A randomized, double-blind placebo-controlled study of the maintenance of efficacy of etanercept plus DMARD(s) compared with DMARD(s) alone in subjects with rheumatoid arthritis after achieving an adequate response with etanercept plus DMARD(s); CRO: Parexel; sponsor: Pfizer **Investigator principal (2013)**
- **PROTOCOL AB 06012:** A phase 2b/3 study to evaluate efficacy and safety of masitinib in comparison to methotrexate in patients with active rheumatoid arthritis with inadequate response to methotrexate or to any disease-modifying antirheumatic drug; CRO: HT Research RO; sponsor AB Science; **Investigator principal (2013)**
- **PROTOCOL PRINT Study, TcLand:** Validation study of RA-INF-Dx as multigene molecular in vitro blood test intended to aid in the identification of patients with rheumatoid arthritis who are unlikely to shown an initial response to infliximab and methotrexate combination therapy ("Predict non-response to Infliximab therapy study") (2011-2012); sponsor: TcLand Expression; CRO: Premier Research **Investigator principal (2012);**

#### Subinvestigator (membru in echipa proiectului) sau coordonator de studiu (44)

1. **PROTOCOL M12-965 EudraCT 2014-001471-31:** Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT) **Subinvestigator** (2014-in desfasurare); sponsor Abbvie
2. **PROTOCOL EFC 10832:** A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF- $\alpha$  antagonists; CRO: Covance; sponsor: Sanofi; **Subinvestigator** (2013 – 2014)
3. **PROTOCOL CD-IA-MEDI-546-1013:** A phase 2, randomized study to evaluate the efficacy and safety of medi-546 in subjects with systemic lupus erythematosus; CRO: INC Research; sponsor: Medimmune; **Subinvestigator** (2013 – in desfasurare);
4. **PROTOCOL CNTO136ARA3002:** A study of CNTO 136 (sirukumab), administered subcutaneously, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug (DMARD) therapy (SIRROUND); CRO: Parexel; sponsor: Janssen; (2013 – in desfasurare);
5. **PROTOCOL RA 0055:** A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical response in the treatment of DMARD-naïve adults with early active rheumatoid arthritis; CRO: Parexel; sponsor: UCB (2013 – 2014);
6. **PROTOCOL I4V-MC-JADV** a randomized, double-blind, placebo and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy; CRO: ICON; sponsor: Eli Lilly; (2013 – in desfasurare);
7. **PROTOCOL I4V-MC-JADY:** a phase 3, multicenter study to evaluate the long-term safety and efficacy of baricitinib in patients with rheumatoid arthritis; CRO: ICON; sponsor: Eli Lilly; (2013 – in desfasurare);
8. **PROTOCOL H9B-MC-BCDP:** a phase 3, multicenter, open label study to evaluate the long-term safety and efficacy of LY2127399 in patients with Rheumatoid Arthritis; CRO: Quintiles; sponsor Eli Lilly; 2012-2013;

9. **PROTOCOL H9B-MC-BCDM:** a phase 3, multicenter, randomized, double blind placebo controlled study to evaluate the efficacy and safety of sc LY2127399 in patients with moderate to severe Rheumatoid Arthritis who had an inadequate response to methotrexate therapy; CRO: Quintiles; sponsor: Eli Lilly; (2012-2013);
10. **PROTOCOL H9B-MC-BCDT:** a phase 3, multicenter, randomized, double blind placebo controlled study to evaluate the efficacy and safety of sc LY2127399 in patients with Systemic Lupus Erythematosus; CRO: Parexel; sponsor: Eli Lilly; (2012-2013);
11. **PROTOCOL H9B-MC-BCDO:** a phase 3, multicenter, randomized, double blind placebo controlled study to evaluate the efficacy and safety of sc LY2127399 in patients with Rheumatoid Arthritis with or without background of Disease Modifying Anti-Rheumatic Drug(DMARD) therapy; CRO: Quintiles; sponsor: Eli Lilly; (2012-2013);
12. **PROTOCOL H9B-MC-BCDX:** a phase 3b, multicenter, open-label study to evaluate the long-term safety and efficacy of subcutaneous LY2127399 in patients with systemic lupus erythematosus (SLE) (illuminate-x); CRO: Parexel; sponsor: Eli Lilly (2012-2013);
13. **PROTOCOL Novartis CAIN457F2306:** A randomized double-blind placebo-controlled multicenter study, Novartis, (2012-2013);
14. **PROTOCOL WA22762:** A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis; CRO: Comac sponsor Hoffman La Roche, Sub-investigator, 2010 -2104;
15. **PROTOCOL ENTRACTE:** A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA);CRO: Quintiles; sponsor: Hoffmann-LaRoche, S (2012- in desfasurare)
16. **PROTOCOL I4V-MC-JADA:** A randomized, double blind placebo controlled, dose ranging, parallel group, phase 2b study in patients with active RA on MTX background therapy sponzor: Eli Lilly; CRO Parexel, 2010 - 2014
17. **PROTOCOL Protocol I1F-MC-RHAK:** studiu faza II cu doze variabile, subcutanate multiple de LY2439821 (Ac anti IL-17) la pacienti cu artrita reumatoida activa care urmeaza tratament concomitent cu DMARD; sponsor: Eli Lilly;, 2010 - 2013
18. **PROTOCOL** A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs' TNF Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNF-biological therapy-sponsor Neovasc; CRO Genexion, 2010 - 2011
19. **PROTOCOL P06129 GO-MORE:** Un studiu cu design deschis (open-label),pentru a evalua adaugarea de Golimumab Subcutanat (GLM) la terapia conventionala cu medicamente modificatoare de boala (DMARD) la pacientii cu Artrita Reumatoida naivi la terapia biologica (Partea 1) urmata de un studiu randomizat ce evalueaza valoarea terapiei combinate cu GLM administrat intravenous si subcutanat in scopul inducerii si mentinerii remisiunii(Partea 2); **MSD**, , 2010 – 2012
20. **PROTOCOL TRU-015-3206K1-2203-WW:** a randomized, parallel, double-blind, placebo controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in subjects with active seropositive Rheumatoid Arthritis on a stable background of methotrexate; sponsor & CRO: Wyeth;, 2009-2011 ;
21. **PROTOCOL A3921024:** A long term, open label follow up study of CP-690.550, a moderately selective Janus kinase 3 inhibitor, for treatment of Rheumatoid Arthritis. Sponsor & CRO: Pfizer;, 2009-in desfasurare
22. **PROTOCOL RADAR: PROTOCOL P05320,** Observational Trial on the value of diagnostic criteria in the diagnosis of spinal spondylarthropathies in patients with chronic low back pain; *Recognizing and Diagnosing Ankylosing Spondylitis Reliably*; sponsor MSD; 2009-2010 (
23. **PROTOCOL BT971:** studiu randomizat, controlat placebo, dublu orb cu esaladarea dozei pentru a evalua eficacitatea, siguranta, si tolerabilitatea medicatiei de studiu BT971 la pacienti cu artrita reumatoida cu tratament concomitent cu MTX; sponsor: Biotest AG

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>Germany; CRO: IFE Romania, , 2009-2010</p> <p>24. <b>PROTOCOL H8C-MC-LQBG:</b> <i>A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain;</i> sponsor: Eli Lilly,; 2008-2009;</p> <p>25. <b>PROTOCOL WA20496:</b> <i>A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of Ocrelizumab given as a single infusion or dual infusion compared with placebo in patients with active Rheumatoid Arthritis who have an inadequate response to methotrexate therapy;</i> Sponsor: Hoffmann La Roche; CRO: Quintiles Romania; 2008-2011;</p> <p>26. <b>PROTOCOL ROB 803-09-002:</b> <i>a phase II, randomized, double-blind, multicenter placebo-controlled, dose-ranging, parallel study group to evaluate the efficacy and safety of orally administered Rob 803 when added to stable MTX in patients with moderate or severe active Rheumatoid Arthritis;</i> Sponsor: Oxypharma; CRO: Pharm-Olam,; 2008-2009 ;</p> <p>27. <b>PROTOCOL LJP 394-90-14:</b> <i>A randomized, double-blind, placebo controlled, three arm, parallel group, multicenter, multinational safety and efficacy trial of 300 mg and 900 mg of Abetimus Sodium in SLE patients with a history of renal disease;</i> sponsor: La Jolla International; CRO: Pharm-Olam; 2008-2009; (</p> <p>28. <b>PROTOCOL WA20499:</b> <i>A randomized, double-blind placebo controlled parallel group multicenter study to evaluate the efficacy and safety of two doses of Ocrelizumab in patients with active SLE;</i> Sponsor: Hoffmann-La Roche Ltd/ Genetech Inc; CRO: Quintiles Romania, , 2008-2009;</p> <p>29. <b>PROTOCOL IP-004:</b> <i>studiu faza IIB, multicentric, randomizat, dublu orb, placebo-controlat pentru evaluarea sigurantei, tolerantei si eficacitatii a doua doze de studiu IPP 201101 subcutanat plus terapia standard, in comparatie cu placebo la pacientii cu LES;</i> sponsor: Immupharma; CRO: Genexion,; 2008-2009 ;</p> <p>30. <b>PROTOCOL A3921035:</b> <i>a phase II B, randomized, double blind, placebo controlled active comparator, multicenter study to compare 5 dose regimens of CP-690.550 and adalimumab versus placebo, administered for 6 months in the treatment of subjects with active Rheumatoid Arthritis.</i> Sponsor &amp; CRO: Pfizer, , 2008-2009 ; (</p> <p>31. <b>PROTOCOL D1520C00001:</b> <i>a randomized, double-blind (with open comparator Etanercept), placebo-controlled, phase IIB multicenter study to evaluate the efficacy of 4 doses of AZD9056 administered for 6 months on the signs and symptoms of Rheumatoid Arthritis in patients with active disease receiving background MTX or Sulphasalazine;</i> sponsor: Astra-Zeneca; CRO: Verum; r, 2008-2009 ; (</p> <p>32. <b>PROTOCOL MDX 1100-04:</b> <i>a phase II, multi-dose, double-blind, placebo controlled, randomized, multicenter study of MDX-1100 (anti CXCL 10 Human Monoclonal Antibody) in patients with active Rheumatoid Arthritis;</i> sponsor: Medarex; CRO: PSI Pharma; 2008-2009;)</p> <p>33. <b>PROTOCOL ACT5488:</b> <i>Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis; :a 4 week, multicenter, randomized, double-blind, placebo-controlled parallel group study of 90 mg administered once daily and 90mg once every other day;</i> Sponsor Sanofi-Aventis; CRO: I3 research; , 2007-2008;</p> <p>34. <b>PROTOCOL P04422:</b> <i>A randomized, multicenter, international open label study of infliximab plus methotrexat versus methotrexat alone for the treatment of methotrexate naive subjects with active psoriatic arthritis;</i> sponsor &amp; CRO: Schering Plough Central East AG; faza IV; 2007-2008;</p> <p>35. <b>PROTOCOL:</b> <i>A phase 2 multicenter randomized double-blind placebo-controlled parallel-group dose finding study of the safety and efficacy of daily CF101 administered orally when added to weekly methotrexate in patients with active rheumatoid arthritis;</i> Sponsor Can-fite Bio-Pharma Ltd; CRO: Pharm Olam International; 2006-2007;</p> <p>36. <b>PROTOCOL WA17047:</b> <i>A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexat compared to methotrexate alone, in methotrexat –naïve patients with active rheumatoid arthritis;</i> Sponsor: Hoffmann-La Roche Genentech; CRO: Parexel, 2006-2010;</p> <p>37. <b>PROTOCOL P1-0205:</b> <i>Efficacy and safety of FASU1 versus FASU2 in a 180 day</i></p> |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                            | <p>study treatment in patients with osteoarthritis of the knee; Sponsor Laboratoires Expascience; CRO: CRC Pharmaceuticals, 2006-2007;</p> <p>38. <b>PROTOCOL F1J-MC-HMEP.</b> <i>Duloxetine 60 to 120mg versus placebo in the treatment of patients with Osteoarthritis knee pain</i>; sponsor si CRO: Eli Lilly Romania SRL; 2006-2007;</p> <p>39. <b>PROTOCOL D1520C05287.</b> <i>A randomized double-blind, placebo-controlled, parallel group, ascending dose study to assess the activity, safety and tolerability of 2 doses of AZD9056 for 4 weeks in patients with active rheumatoid arthritis receiving methotrexate and/or sulphasalazine</i>, phase II; sponsor Astra Zeneca; CRO Parexel International SRL, 2005-2006; (Investigator principal prof Chirieac R) (adeverinta 34/05.01.2015)</p> <p>40. <b>PROTOCOL MDT3-005.</b> <i>A two-arm study comparing the analgesic efficacy and safety of Tramadol HCl once-a-day versus placebo for the treatment of pain due to osteoarthritis of the knee</i>; CRO: Parexel International; <b>coordonator studiu</b>, 2005-2006; (Investigator principal prof Chirieac R) (adeverinta 38/05.01.2015)</p> <p>41. <b>PROTOCOL H4Z-MC-GJAD.</b> <i>Effects of Arzoxifene on vertebral fracture incidence and on invasive breast cancer incidence in postmenopausal; women with osteoporosis or with low bone density</i>; Sponsor Ely Lilly and Company; CRO: Quintiles Romania; 2004-2009;</p> <p>42. <b>PROTOCOL MI-CP100:</b> <i>A phase II, randomized, double -blind study to evaluate the effects of MEDI-522, a humanized monoclonal antibody to integrin alpha V beta 3 on disease activity and progression of joint damage in patients with active rheumatoid arthritis sub-optimally responding to methotrexat</i>; sponsor Medimmune; CRO: PSI Pharma Support Romania SRL; <b>coordonator studiu</b>, 2003-2004;</p> <p>43. <b>PROTOCOL</b> <i>Studiu multicentric, de faza III, randomizat, asupra tolerabilitatii Tramadol la pacienti cu atroza de genunchi</i>; Parexel International, <b>coordonator studiu</b>, 2003-2004;</p> <p>44. <b>PROTOCOL</b> <i>Studiu multicentric, de faza III, randomizat, dublu orb, placebo-controlat asupra tolerabilitatii gastro-intestinale a combinatiei terapeutice diclofanac-misoprostol (ArthrotecR) la pacienti cu atroza genunchi</i>; <b>coordonator studiu</b>, 1998-1999;</p> |
| <b>Citari ISI/BDI</b>                                                      | <ul style="list-style-type: none"> <li>• <b>388 citari ISI, H index=9</b></li> <li>• <b>1448 citari Google scholar, h-index 17</b></li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coordonator/Lector<br/>Cursuri Postuniversitare/<br/>EMC/ masterate</b> | <ul style="list-style-type: none"> <li>• proiecte educationale internationale (1 coordonator, 1 membru)</li> <li>• coordonator cursuri postuniversitare EMC acreditate, Facultatea Medicina, UMF "Gr.T.Popa" Iasi (8)</li> <li>• proiecte de educatie continua nationale (membru) (4)</li> <li>• lector cursuri postuniversitare formare continua (23), masterate (2)</li> <li>• membru in comitete stiintifice, organizator de manifestări stiintifice (18)</li> <li>• lector la manifestari stiintifice: 110 manifestari nationale</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Lucrări Licență</b>                                                     | <ul style="list-style-type: none"> <li>• 74 lucrari licenta Facultatea de Medicina (42 limba engleza); 14 lucrari indrumate Facultatea Bioinginerie; 3 lucrari in dubla coordonare (&amp;cadru didactic disciplina Ergonomie, Facultatea Stomatologie)</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Brevete inventie</b>                                                    | <ul style="list-style-type: none"> <li>• Brevete de inventie: 2 internationale</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Premii si Distincții</b>                                                | <ul style="list-style-type: none"> <li>▪ 2016, Premiu Societatea Română de Reumatologie pentru lucrarea <b>Exista vasculopatie periferica in miozita anti-tRNAsintetaza pozitiva?</b> Pomirleanu C, Strugariu G, Resmerita I, Axinte A, Petrariu L, ANCUTA C C. E-poster la Congresul Național de Reumatologie 2016, București</li> <li>▪ 2016, Premiu Societatea Română de Reumatologie pentru lucrarea <b>Algoritmul DETECT in screening-ul hipertensiunii arteriale pulmonare la pacienti cu</b></li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |



|                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Afilieri academice/<br/>societati profesionale</b></p>            | <p><b>sclerodermie sistemică: studiu preliminar.</b> R Maxim, C Pomirleanu, A Manta, F Mitu, <b>ANCUTA C.</b> E-poster la Congresul Național de Reumatologie 2016, București</p> <ul style="list-style-type: none"> <li>• 2015, premiere rezultate cercetare PN-II-RU-PRECISI, <i>An observational cohort study of patients with newly diagnosed DU secondary to systemic sclerosis registered in the EUSTAR database</i>, Clin and Exp Rheumatol</li> <li>• 2015, premiu SRR, <i>Densitatea minerală osoasă și riscul de fractură în sclerodermia sistemică: experiența unui centru EUSTAR</i>, <b>ANCUTA C</b> et al, oral-poster CNR 2015</li> <li>• 2014, Premiu <i>Excelenta în Reumatologie</i>, Societatea Romana de Reumatologie, <i>Model matematic de predicție a obținerii remisiunii SDAI în poliartrita reumatoidă</i>, Trifan AE, Pomirleanu C, Miu S, <b>ANCUTA C</b>, comunicare orală la CNR 2014 Bucuresti, Romania;</li> <li>• 2009, <i>Premiul de excelenta în medicina TNL</i>, Gala Tinerilor valori editia IV, 24 feb, Iasi, Romania</li> <li>• 2008, <i>Diploma de merit</i>, lucrarea <b>Terapia cu Infliximab și sarcina – o provocare a etapei moderne</b>, Cardei M, <b>ANCUTA C</b>, Ancuta E, Stoica S, Zugravu G, Chirieac R, Sesiunea comunicari orale Simpozionul Conect 2008 – Remicade la puterea a 6-a, 30 mai 2008, Bucuresti, Romania;</li> <li>• 2008, <i>Mentiune</i> lucrarea <b>Infliximab, eficacitate și tolerabilitate în artropatia psoriazică</b>, <b>ANCUTA C</b> et al, sesiunea postere, Simpozionul Conect 2008 – Remicade la puterea a 6-a, 30 mai 2008, Bucuresti, Romania;</li> <li>• Recunoastere <i>Marquis Who's Who</i>; <i>Ancuta Codrina Mihaela Irena is recognized in Marquis Who's Who</i>: physician, educator, Location: Iasi; Country: Romania;<br/><a href="http://bios.marquiswhoswho.com/ancuta_codrina_mihaela irena/physician_educator/8309281">http://bios.marquiswhoswho.com/ancuta_codrina_mihaela irena/physician_educator/8309281</a></li> </ul> <p><b>Internationale</b></p> <ul style="list-style-type: none"> <li>• <b>EUSTAR</b> (<i>EULAR Scleroderma Trials and Research</i>);</li> <li>• <b>IASP</b> (<i>International Association for the Study of Pain</i>) și SIG Musculoskeletal pain (subgroup durere musculo-scheletala)</li> <li>• <b>ECTS</b> (<i>European Calcified Tissue Society</i>)</li> <li>• <b>EMEUNET (alumni)</b></li> <li>• <b>Autoimmunity network</b></li> <li>• <b>SLEuro, European Lupus Society</b></li> <li>• <b>World Scleroderma Foundation</b></li> </ul> <p><b>Nationale</b></p> <ul style="list-style-type: none"> <li>• <b>Societatea Romana de Reumatologie</b>;</li> <li>• <b>Asociatia de Recuperare Nord Est</b> (membru fondator; 2009)</li> <li>• <b>RHEUMA-NORD EST</b> – asociatie profesionala reumatologie (presedinte și membru fondator; 2014)</li> <li>• <b>Colegiul Medicilor din Romania</b> (CMI 2409/05.10.2011)</li> </ul> |
| <p><b>MEMBRU ÎN<br/>COMITETE<br/>ȘTIINȚIFICE ȘI<br/>REDAȚIONALE</b></p> | <ul style="list-style-type: none"> <li>• Membru în Colegiul de Redacție al Revistei Romane de Reumatologie_</li> <li>• <i>Invited peer-reviewer</i> reviste cotate ISI (<i>Clinical Rheumatology, European Journal of Physical and Rehabilitation Medicine</i>);</li> <li>• Membru consiliul <i>peer-review</i> al Revistei Romane Reumatologie (Editura</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

Medicala Amaltea, Bucuresti; ISSN: 1843-0791; eISSN: 2069-6086, Cod CNCISIS: 378, B+)

- Invited peer-reviewer reviste BDI (*Journal of Dentistry, Medicine and Medical Sciences*)

## ANEXA LUCRARI

### A. Teza de doctorat

*Miopatia inflamatorie in poliartrita reumatoida* (seria E nr. 0002743, ordin MEC nr 3824/03.05.2006)

### B. Cărți si capitole în cărți publicate în ultimii 10 anii

#### Carti

1. **ANCUTA C**, *Miopatiile inflamatorii idiopatice – Concepte fiziopatologice, diagnostice si terapeutice actuale*, ed. „Gr.T.Popa” UMF Iasi 2014, ISBN 978-606-544-258-0
2. **ANCUTA C**, *Insights and perspectives in rheumatology*, ed. „Gr.T.Popa” UMF Iasi, 2014, ISBN 978-606-544-278-8
3. sub redactia **ANCUTA C**, *Esentialul in Medicina Fizica si Recuperare Medicala*, Ed „Gr.T.Popa” UMF Iasi, 2010, ISBN: 978-606-544-031-9
4. **ANCUTA C**, Gheorghiu E, Miu S, Dan L. *Manevre si tehnici de kinetoterapie in recuperarea medicala*, Ed. „Gr.T.Popa” UMF Iasi, 2010, ISBN: 978-606-544-039-5
5. **ANCUTA C**, *Clinica si tratamentul complex al principalelor boli reumatismale*, Iasi 2009, Ed „Gr.T.Popa” UMF Iasi, ISBN: 978-973-7682-78-9
6. **ANCUTA C**, *Elemente de diagnostic, evaluare si monitorizare in patologia reumatismala*, Iasi 2009, Ed „Gr.T.Popa” UMF Iasi, ISBN: 978-973-7682-91-8
7. Chirieac R, **ANCUTA C**, *Notiuni de balneofizioterapie*, Ed“Gr.T.Popa” UMF Iasi 2009, ISBN: 978-973-7682818-9

#### Capitole in carti

8. **ANCUTA C**, Pomirleanu C, Mihailov C, Ancuta E, Opris D, *BAFF System in Rheumatoid Arthritis: from Pathobiology to Therapeutic Targets*, New Developments in the Pathogenesis of Rheumatoid Arthritis, Prof. Lazaros Sakkas (Ed.), InTech, DOI: 10.5772/66580, ISBN 978-953-51-2970-7, Print ISBN 978-953-51-2969-1, pp 65-79
9. **ANCUTA C**, Iordache C, Ancuta E, Mihailov C, *Rheumatoid Arthritis and Periodontal Disease: A Complex Interplay*, New Developments in the Pathogenesis of Rheumatoid Arthritis, Prof. Lazaros Sakkas (Ed.), InTech, DOI: 10.5772/65863, ISBN 978-953-51-2970-7, Print ISBN 978-953-51-2969-1, pp 101-120
10. **ANCUTA C**, *Bisfosfonatii: eficacitate*. In: Osteoporoza si alte boli metabolice osoase - Syllabus; Editor Galeasanu C, Ed Gr.T.Popa UMF Iasi 2017, ISBN: 978-606-544-473-9; pg 245-259
11. Pomirleanu C, **ANCUTA C**, *Evaluarea videocapilaroscopica a vasculopatiei periferice din sclerodermia sistemica*, in: Noi frontiere in dermatologie, Ed. Junimea Iasi 2016, sub redactia Branisteanu DE, ISBN 978-973-37-1926-7, pg 47-55
12. **ANCUTA C**, Pomirleanu C, Ancuta E, *Vasculopatia digitala din sclerodermia sistemica – concept patogenice si terapeutice actuale*, in: Noi frontiere in dermatologie, Ed. Junimea Iasi 2016, sub redactia Branisteanu DE, ISBN 978-973-37-1926-7, pg 56-67
13. **ANCUTA C**, Chirieac R, Fatu AM, Tanculescu O, Iordache C, *Incidenta si prevalenta patologiei musculo-scheletale la medicii dentisti si implicarea factorilor de risc profesionali*, In: Managementul preventiv si interceptiv al afectiunilor stomatologice la copil si adult tanar. Ed. „Gr.T.Popa” UMF Iasi 2016, sub redactia Zetu I, Balan A, ISBN: 978-606-544-392-1, pg 367-380
14. **ANCUTA C**, Chirieac R, Pomirleanu C, Iordache C, *Kinetoterapia - mijloc de prevenire a patologiei musculo-schelerale la medical dentist*, In: Managementul preventiv si interceptiv al afectiunilor stomatologice la copil si adult tanar. Ed. „Gr.T.Popa” UMF Iasi 2016, sub redactia Zetu I, Balan A, ISBN: 978-606-544-392-1, pg 354-365



15. **ANCUTA C**, *Osteoporoza glucocorticoid-indusa*, In: Osteoporoza o abordare multidisciplinara, Syllabus, editor Corina Galesanu, ed. "Gr.T.Popa", Universitatea de Medicina si Farmacie Iasi 2016 ISBN: 978-606-544-385-3:141-154
16. **ANCUTA C**, Chirieac R, *Osteoporoza si inflamatie*, In: Osteoporoza o abordare multidisciplinara, Syllabus, editor Corina Galesanu, ed. "Gr.T.Popa", Universitatea de Medicina si Farmacie Iasi 2016 ISBN: 978-606-544-385-3:113-120
17. Iordache C, Fatu AM, Vasca B, Diaconescu S, Chirieac R, **ANCUTA C**, *Aspecte de patologie musculo-scheletala la medicul dentist*, In: Medicina si Fenomenul migratiei – o abordare interdisciplinara, editor Leon LI, Ed. Gr.T.Popa UMF Iasi 2016, ISBN 978-606-544-398-3, pg 263-272
18. **ANCUTA C**, Pomirleanu C, *Reacții cutanate paradoxale la inhibitorii de TNF în patologia inflamatorie imun mediate*, in: Frontiere interdisciplinare în dermatologie, Ed. Junimea Iași 2015, sub redacția Daciana Elena Brănișteanu, ISBN 978-973-37-1838-3 (pg 89-90);
19. **ANCUTA C**, Pomirleanu C, *Subseturi clinico-serologice în miopatiile inflamatorii idiopatice*, in: *Frontiere interdisciplinare în dermatologie*, Ed. Junimea Iași 2015, sub redacția Daciana Elena Brănișteanu, ISBN 978-973-37-1838-3, pg 251-260
20. **ANCUTA C**, *Osteoporoza la barbat*. In: Galesanu C. (ed), Osteoporoza (de la diagnostic la tratament) – o provocare pentru practician, Ed UMF Gr.T.Popa Iasi 2013, ISBN 978-606-544-131-6; pg. 431-441
21. **ANCUTA C**, *Osteoporoza glucocorticoid indusa*. In: Galesanu C. (ed), Osteoporoza (de la diagnostic la tratament) – o provocare pentru practician, Ed. UMF Gr.T.Popa Iasi 2013, ISBN 978-606-544-131-6; pg. 487-507
22. **ANCUTA C**, Ancuta E, Chirieac R (2011), *Aminoacyl-tRNA synthetases In Idiopathic Inflammatory Myopathies: An Update on Immunopathogenic Significance, Clinical and Therapeutic Implications*, in: 'Idiopathic Inflammatory Myopathies - Recent developments, edited by Gran JT, Published by InTech; ISBN 978-953-307-694-2, pp.77-90
23. **ANCUTA C**, Ancuta E, Chirieac R (2011), *Pregnancy in myositis: challenges and pitfalls*, in: 'Idiopathic Inflammatory Myopathies - Recent developments, edited by Gran JT, Published by InTech; ISBN 978-953-307-694-2, pp 197-212
24. **ANCUTA C**, *Durerea cronică musculo-scheletală*. In: Mungiu OC, Jaba IM (ed) Managementul durerii – ghid practic (grant IASP: Initiative for Improving Pain Education), Editura "Gr.T.Popa", UMF Iasi 2010, ISBN: 978-973-7682-98-7 (pg 113-142)
25. **ANCUTA C**, *Managementul non-farmacologic al durerii cronice musculo-scheletale*. In: Mungiu OC, Jaba IM (ed) Managementul durerii – ghid practic (grant IASP: Initiative for Improving Pain Education), Editura "Gr.T.Popa", UMF Iasi 2010, ISBN: 978-973-7682-98-7, pg 206-210
26. **ANCUTA C**, *Tulburari de crestere in artrita cronica juvenila*. In: Galesanu C (ed) *Tulburari de crestere staturala si ponderala*, Iasi 2007, Ed. "Gr.T.Popa", Iasi, pg ISBN 978-973-7682-11-6

### C. Lucrări indexate ISI/BDI publicate în ultimii 5

Data: 11 SEPT 2019

Semnatura: dr. C. Ancuta

